title: Dipeptide "alaptide" prevented impairments in spontaneous behavior produced with trimethyltin in male rats.
abstract: OBJECTIVE
  On the animal model of trimethyltin (TMT) induced behavioral deficits the effect of chronic treatment with spirocyclic dipeptide cyclo/alanyl-l-amino-l-cyclopentane-carbonyl (alaptide, AL) was evaluated in adult male rats.
  
  
  METHODS
  Changes in the spontaneous behavioral repertoire were investigated in the open-field test on Day 21 (Session 1) and Day 28 (Session 2) after a single oral TMT administration.
  
  
  RESULTS
  In Experiment 1, rats given the highest TMT dose (7.5 mg/kg) exhibited significantly increased total number of behavioral patterns, the floor sniffing being the most frequent pattern. While the medium TMT dose (5 mg/kg) had a similar effect only in Session 1, the lowest TMT dose (2.5 mg/kg) was entirely ineffective. In Experiment 2, an explicit beneficial influence of both AL doses (5 and 10 mg/kg) given for 10 days before and 10 days after TMT (7.5 mg/kg) on the spontaneous behavior repertoire was observed in both Session 1 and Session 2. The total number of patterns and the time spent in individual patterns of AL+TMT treated animals did not differ from the controls and those given AL alone.
  
  
  CONCLUSIONS
  We conclude that sufficiently long AL treatment interfered with deleterious effects of TMT and forestalled changes in the structure and timing of spontaneous behavioral patterns. Thus, AL can be designated as a substance having "neuroprotective" effects.
authors.affiliation: Laboratory of Biochemical Neuropharmacology, Institute of Medical Biochemistry, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Hlinak
authors.forename: Ivan
authors.initials: I
authors.lastname: Krejci
authors.forename: Sixtus
authors.initials: S
authors.lastname: Hynie
authors.forename: Vera
authors.initials: V
authors.lastname: Klenerova
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009498:Neurotoxins / Q000633:toxicity*; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric; D014298:Trimethyltin Compounds / Q000633:toxicity*
chemical_list: D009479:Neuropeptides; D018696:Neuroprotective Agents; D009498:Neurotoxins; D010456:Peptides, Cyclic; D014298:Trimethyltin Compounds; C046488:trimethyltin; C049178:cyclo(alanine-(1-amino-1-cyclopentane)carbonyl)